-- Days : -- HRS : -- MIN : -- SEC
Register Now →
|Articles|November 1, 2002

Supplements and Featured Publications

  • Use of Selective COX-2 Inhibitors for Chronic Therapy: The Managed Care Perspective
  • Volume 8
  • Issue 17 Suppl

Treatment of Rheumatoid Arthritis and Osteoarthritis Chronic Pain With Cox-2-Selective Inhibitors: A Managed Care Perspective


Related to this article

Kenneth Komorny, PharmD, BCPS | Image: Moffitt Cancer Center
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.